×
News Home

Does Turning Point Therapeutics Inc (TPTX) Have What it Takes to be in Your Portfolio Monday?

Monday, May 16, 2022 01:42 PM | InvestorsObserver Analysts
Does Turning Point Therapeutics Inc (TPTX) Have What it Takes to be in Your Portfolio Monday?

Turning Point Therapeutics Inc (TPTX) is near the top in its industry group according to InvestorsObserver. TPTX gets an overall rating of 75. That means it scores higher than 75 percent of stocks. Turning Point Therapeutics Inc gets a 97 rank in the Biotechnology industry. Biotechnology is number 68 out of 148 industries.

Overall Score - 75
TPTX has an Overall Score of 75. Find out what this means to you and get the rest of the rankings on TPTX!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 75 would rank higher than 75 percent of all stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Turning Point Therapeutics Inc Stock Today?

Turning Point Therapeutics Inc (TPTX) stock is trading at $33.32 as of 1:39 PM on Monday, May 16, a gain of $0.72, or 2.21% from the previous closing price of $32.60. The stock has traded between $31.78 and $34.23 so far today. Volume today is less active than usual. So far 210,399 shares have traded compared to average volume of 768,151 shares. Click Here to get the full Stock Report for Turning Point Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App